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Abstract: Palonosetron (Aloxi®, Onicit®, Paloxi®) is a second-generation 5-HT3 receptor 
antagonist (RA) with an extended half-life of ~40 hours and high binding afﬁ  nity for the 5-HT3 
receptor that is markedly different from other 5-HT3 RAs. Phase III trials demonstrate that a 
single dose of palonosetron compared with traditional 5-HT3 RAs is more effective in prevent-
ing chemotherapy-induced nausea and vomiting (CINV) during the ﬁ  rst 24 hours following 
chemotherapy (acute CINV), and also exhibits prolonged efﬁ  cacy to provide signiﬁ  cantly better 
protection from CINV in the delayed and overall phases. This superior and extended protection 
from CINV conferred by palonosetron following a single intravenous dose before chemotherapy 
simpliﬁ  es dosing schedules. Recent research has focused on optimization of palonosetron-based 
antiemetic regimens, particularly in combination with steroids and neurokinin-1 RAs. The avail-
able clinical data indicate high control rates for palonosetron, suggesting a synergistic potential 
for protection in patients scheduled to receive emetogenic drug regimens.
Keywords: palonosetron, CINV , 5-HT3 receptor antagonists, moderately emetogenic chemo-
therapy (MEC), highly emetogenic chemotherapy (HEC)
Introduction
Complete control of chemotherapy-induced nausea and vomiting (CINV) remains 
a primary goal of chemotherapy treatment (Koeller et al 2002). Some 15 years 
after the launch of the ﬁ  rst-generation 5-HT3 receptor antagonists (5-HT3 RAs), 
available in Europe or North America such as ondansetron (Zofran®, GlaxoSmith-
Kline), granisetron (Kytril®, Roche), dolasetron (Anzemet®, Aventis), and tropi-
setron (Navoban®, Novartis), which heralded a major advance in the treatment of 
acute CINV, some patients are still not treated adequately. Failure to gain effective 
control over CINV can have important consequences that may include extended or 
unplanned hospitalization or delay or refusal of chemotherapy as a result of vomiting 
and nausea, potentially leading to a reduction in antineoplastic efﬁ  cacy (Grunberg 
et al 2000). Despite efforts to combat CINV , it remains one of the worst side effects 
experienced (Table 1) (Coates et al 1983; Grifﬁ  n et al 1996; de Boer-Dennet et al 
1997; Lindley et al 1999; Grunberg et al 2000; Koeller et al 2002), with 59% of 
patients reporting nausea to such an extent that it severely impacts daily living 
(De Moor et al 2003).
CINV can be categorized in simpliﬁ  ed regulatory terms as either acute (up to 
24 hours postchemotherapy) or delayed (after 24 hours postchemotherapy), while 
chemotherapy regimens are subdivided into levels 1–5 according to their emetogenic 
potential. Among them, level 3–4 regimens result in an emesis frequency of 30%–90%, 
and are traditionally considered moderately emetogenic (MEC), while level 5 results 
in  90% patients experiencing emesis with highly emetogenic (HEC) chemotherapy 
(Hesketh et al 1997).Therapeutics and Clinical Risk Management 2007:3(6) 1010
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International guideline development is a continuous and 
dynamic effort towards indication of the better antiemetic 
treatment in light of the most recent data published in lit-
erature. According to the most recent indication for CINV 
prevention, 5HT3 RAs are unanimously recognised to be 
the foundation of antiemetic therapy. 5HT3 RAs should 
then be given in combination with other antiemetic agents, 
usually corticosteroids such as dexamethasone and NK1 
RAs, in accordance to the evaluation of patient-related and 
treatment-related risk factors, in particular the chemotherapy 
emetogenicity (HEC or MEC).
Although current regimens are considered to be quite 
effective in treating acute CINV , adequate control of 
delayed symptoms needs improvement. A recent study 
found acute emesis in 13% and 12% of patients receiving 
MEC and HEC, respectively, while over 37% and 33% 
experienced acute nausea with these respective treatments, 
despite the use of ﬁ  rst-generation 5-HT3 RAs plus con-
comitant corticosteroids as recommended by international 
guidelines (Figure 1) (Grunberg, Vanden Burgt et al 2004). 
Furthermore, delayed emesis was evident in 28% and 50% 
of patients in the MEC and HEC groups, respectively, while 
delayed nausea was experienced by 52% and 60% of these 
respective patients (Grunberg, Vanden Burgt et al 2004). 
Furthermore the extent of CINV is underestimated by 
both physicians and nurses treating these patients (Figure 
1) (Eisenberg, Rubenstein et al 2003; Grunberg, Deusson 
Burgt et al 2004). Clearly, CINV remains a substantial and 
underrecognized burden.
Emesis is believed to be due to complex interactions 
between a number of neurotransmitters (serotonin (5-HT), 
neurokinin, dopamine, histamine, and acetylcholine) and 
receptor subtypes within gastrointestinal (GI) and central 
pathways. Stimulation of serotonin release from entero-
chromafﬁ  n cells of the GI mucosa is thought to be a major 
pathway, which triggers emesis through stimulation of the 
medulla via vagal afferents. There are two central medullary 
areas implicated, namely the chemoreceptor trigger zone 
(CTZ) and the vomiting centre. The CTZ integrates blood-
borne chemical signals with neuronal inputs from the GI 
tract, and efferents from the CTZ then signal the collection of 
brainstem nuclei known as the vomiting centre. The vomiting 
centre integrates visceral and somatic functions, resulting in 
the process of vomiting (Figure 2) (Hornby 2001).
5-HT3 receptor antagonists
The ﬁ  rst generation of 5-HT3 RAs – ondansetron, granisetron, 
dolasetron, and tropisetron – are remarkable by virtue of their 
similarities rather than differences and have similar efﬁ  cacies 
in preventing acute CINV when administered at therapeuti-
cally equivalent doses, although they have a more limited 
impact on delayed symptoms (Hesketh 2000). They are 
widely believed to be similar to the point that until recently 
they have been regarded as therapeutically equivalent and 
interchangeable in clinical guidelines (Koeller et al 2002). 
A more detailed observation and the advent of the second-
generation 5-HT3 RA palonosetron is, however, changing 
this ethos.
Palonosetron: a second-generation 
5-HT3 receptor antagonist
Palonosetron (Figure 3) is the ﬁ  rst 5-HT3 RA to show an 
efﬁ  cacy that is superior to other 5-HT3 RAs against CINV 
due to MEC in FDA registration trials (Eisenberg et al 2003; 
Gralla et al 2003; Rubenstein et al 2003). It was ﬁ  rst approved 
by the FDA in 2003 and is currently licensed in the USA for 
the prevention of acute nausea and vomiting associated with 
MEC and HEC, and the prevention of delayed nausea and 
vomiting associated with MEC. More recently, palonosetron 
has gained approval in Europe for the prevention of acute 
nausea and vomiting associated with HEC, and the preven-
tion of nausea and vomiting associated with MEC. It is 
Table 1 Patient perceptions of the most severe side effects of cancer chemotherapy
Rank 1983a 1993b 1995c   1999d 
1 Vomiting  Nausea  Nausea  Nausea
2  Nausea  Constantly tired  Loss of hair  Loss of hair
3  Loss of hair  Loss of hair  Vomiting  Constantly tired
4  Thought of coming  Effect on family  Constantly tired  Vomiting
 for  treatment  
5  Length of time   Vomiting  Having to have  Changes in the way
  treatment takes    injections  things taste
a(Coates et al 1983)
b(Grifﬁ  n et al 1996)
c(de Boer-Dennert et al 1997)
d(Lindley et al 1999)Therapeutics and Clinical Risk Management 2007:3(6) 1011
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postulated that the superior clinical efﬁ  cacy of palonosetron, 
including the control of delayed CINV following a single 
dose prior to chemotherapy, can be related to the  30-fold 
higher binding afﬁ  nity for the 5-HT3 receptor subtype and a 
4–10-fold longer half-life compared to ﬁ  rst-generation 5-HT3 
RAs (Eisenberg, Figueroa-Vadillo et al 2003; Grunberg et al 
2003). Despite having a longer half-life and higher binding 
afﬁ  nity, however, palonosetron has a similar tolerability 
proﬁ  le to the ﬁ  rst-generation 5-HT3 RAs, demonstrating 
minimal side effects. Headache and constipation are the most 
commonly reported adverse events for both generations of 
5-HT3 RAs (Hesketh et al 1996; Eisenberg, Figueroa-Vadillo 
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Figure 1 Perception vs reality: Healthcare providers’ predictions of incidence, and observed incidence, of nausea and vomiting following chemotherapy (Drawn from data in 
Grunberg, Deusson et al 2004).
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et al 2003; Eisenberg, Rubenstein et al 2003; Gralla et al 
2003; Grunberg et al 2003; Rubenstein et al 2003).
Pharmacokinetics and pharmacodynamics
The pharmacokinetics of palonosetron have been studied both 
in healthy volunteers (Stoltz et al 2004) and cancer patients 
receiving highly emetogenic cisplatin (Eisenberg et al 2004), 
with generally similar kinetics being shown in both studies. 
Intravenously administered palonosetron (0.3–90 µg/kg) 
showed overall elimination half-life values of approximately 40 
hours as result of low clearance values (1.11–3.90 mL/min/kg) 
and a large volume of distribution (3.85–12.6 L/kg). At the 
currently approved IV dose of 0.25 mg, palonosetron shows to 
be widely distributed in the body, with a volume of distribution 
of 8.3 L/kg, and to be bound to plasma proteins at a proportion 
of 62% (Aloxi® prescribing information 2003/2005). 
Palonosetron is metabolized by cytochrome P450 enzymes, 
mainly CYP2D6, with minor contributions from CYP1A2 
and CYP3A4 (Aloxi® prescribing information 2003/2005). 
It is noteworthy that the clinical pharmacokinetic parameters 
are not signiﬁ  cantly different between poor and extensive 
metabolizers of CYP2D6 substrates (Aloxi® prescribing 
information 2003/2005) The major metabolites are N-oxide-
palonosetron and 6-S-hydroxy-palonosetron, both of which 
have a low afﬁ  nity for the 5-HT3 receptor and therefore do 
not contribute to the activity of the parent compound (Aloxi® 
prescribing information 2003/2005).
Drug interactions
Due to its multiple routes of elimination and lack of effect 
on cytochrome P450 isoenzyme induction or inhibition at 
therapeutic concentrations, palonosetron has low potential 
for clinically signiﬁ  cant drug interactions (Aloxi® prescribing 
information 2003/2005). This characteristic is of particular 
value in elderly patients who are often receiving multiple 
medications (Aapro et al 2005). Additionally, no dose 
adjustments are required in the elderly or in patients with 
renal or hepatic impairment (Aloxi® prescribing information 
2003/2005). Likewise palonosetron does not interact 
with antineoplastic drugs; its chemical stability and the 
antitumor activity of these medications are maintained during 
coadministration (Aloxi® prescribing information 2003/2005; 
Cantoreggi et al 2003; Trissel and Zhang 2004a, 2005a, 
2005b; Xu et al 2004; Trissel and Xu 2005). Any interaction 
with dexamethasone would be of particular importance 
as it is usual clinical practice to coadminister a premixed 
solution of dexamethasone and a 5-HT3 RA over 15 min; 
however, the label for palonosetron recommends a much 
quicker intravenous infusion over 30 sec (Aloxi® prescribing 
information 2003/2005). An admixture of palonosetron 
and dexamethasone in polyvinylchloride minibags or in 
polypropylene syringes has been shown to be physically 
compatible and chemically stable for at least 48 hours when 
stored as indicated (Trissel and Zhang 2004b). Furthermore, a 
recent open-label study has evaluated the safety and efﬁ  cacy 
of palonosetron and dexamethasone coadministered over 
10–15 min, which has conﬁ  rmed that coadministration is 
both safe and effective (Hajdenberg et al 2006).
Afﬁ  nity and potency
Palonosetron has at least a 30-fold higher afﬁ  nity for the 
5-HT3 receptor compared to the other ﬁ  rst-generation 5-HT3 
RAs. At clinically relevant doses, it does not display any 
appreciable binding to a range of other receptors, including 
dopaminergic, muscarinic, adrenergic, and opioid receptors 
(Aloxi® prescribing information 2003/2005; Wong et al 1995). 
In addition to a higher afﬁ  nity, intravenously administered 
palonosetron has a higher potency at the 5-HT3 receptor, being 
three-fold more potent than granisetron and up to 55 times 
more potent than ondansetron in animal models (Eglen et al 
1995). The distinct pharmacokinetics and dynamics displayed 
by palonosetron compared to ﬁ  rst-generation 5-HT3 RAs 
appear to translate into a distinct clinical proﬁ  le, providing 
extended relief from CINV (Eisenberg, Rubenstein et al 2003; 
Gralla et al 2003; Eisenberg et al 2004).
Optimizing dosage of palonosetron
The optimal dose of palonosetron was evaluated in a random-
ized, double-blind, multicenter, dose-ranging phase II trial 
Figure 3 Molecular structure of palonosetron hydrochloride.
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(Eisenberg et al 2004). A total of 161 chemotherapy-naïve 
patients (80.0% male) were randomized to one of ﬁ  ve groups 
to receive between 0.3 and 90 µg/kg palonosetron as a single 
intravenous bolus dose 30 min prior to receiving HEC (largely 
high dose cisplatin:  70 mg/m2). The pooled 0.3–1 µg/kg 
dose was chosen as a suboptimal dose. Dexamethasone was 
not given prophylactically and was available only as a rescue 
medication. The primary endpoint was 24-hour complete 
response (CR) (no emesis and no need for rescue medication). 
Efﬁ  cacy was evaluated up to day 7. Complete control was 
included as a secondary endpoint, deﬁ  ned as no emesis, mild 
or no nausea, and no need for rescue medication.
In the 148 evaluable patients, acute CR rates of 40%–50% 
were achieved across the effective dose range (3–90 µg/kg). 
The dose–response curve demonstrated a threshold relation-
ship that is typical for 5-HT3 RAs (Rubenstein et al 2003; 
Eisenberg et al 2004). Complete control in the acute phase 
was achieved in 39%–48% of patients across this dose range 
and again showed a threshold dose–response relationship. 
Prolonged protection following a single dose on day 1 was 
observed up to day 7. Compared with the low efﬁ  cacy of 
the pooled suboptimal cohort of 0.3–1 µg/kg (CR 24%), 
the lowest effective doses were the 3 and 10 µg/kg doses, 
demonstrating 46% and 40% CR rates in the acute period, 
respectively. Based on these data, doses of 0.25 mg and 
0.75 mg (equivalent to 3 µg/kg and 10 µg/kg, respectively) 
were selected for phase III trials.
Efﬁ  cacy
The efﬁ  cacy of palonosetron in the prevention of nausea and 
vomiting induced by chemotherapy has been demonstrated 
in three randomized, stratiﬁ  ed, double-blind, parallel-arm, 
active comparator-controlled phase III trials (Eisenberg, 
Rubenstein et al 2003; Gralla et al 2003; Aapro et al 2006). 
Two of these studies examined efﬁ  cacy of the two selected 
doses of palonosetron, 0.25 mg and 0.75 mg in MEC patients 
compared to ondansetron 32 mg (Gralla et al 2003) or 
dolasetron 100 mg (Eisenberg et al 2003), while the third 
compared the two doses of palonosetron to ondansetron 
32 mg in patients receiving HEC (Aapro et al 2006). All 
pivotal studies were designed to show that at least one of the 
two palonosetron doses (0.25 mg and 0.75 mg) was at least 
as effective as the comparator.
To reﬂ  ect the actual clinical situation, heterogeneous 
mixed-sex study populations were recruited (51%–82% 
female) that were chemotherapy experienced or chemotherapy 
naïve (40%–66% naïve) (Aloxi® prescribing information 
2003/2005; Eisenberg, Figueroa-Vadillo et al 2003; Gralla 
et al 2003). A number of moderately emetogenic agents were 
included in the studied regimens: methotrexate 250 mg/m2, 
cyclophosphamide  1,500 mg/m2, doxorubicin  25 mg/m2, 
cisplatin  50 mg/m2, or any dose of carboplatin (Eisenberg, 
Figueroa-Vadillo et al 2003; Gralla et al 2003). Chemo-
therapy regimens for the HEC study included cisplatin  60 
mg/m2, cyclophosphamide  1,500 mg/m2, and dacarbazine 
(Aapro et al 2006). Either no (Gralla et al 2003) or minimal 
(~5% of patients) (Eisenberg et al 2003) corticosteroids 
were administered in the MEC studies, although 67% of the 
patients in the HEC study received concomitant dexametha-
sone on day 1 (Aapro et al 2006). The primary endpoint of all 
three studies was the CR rate, deﬁ  ned as no emetic episode 
and no use of rescue medication during the ﬁ  rst 24 hours. A 
series of secondary endpoints, such as rates of delayed CR 
(24–120 hours), overall CR (0–120 hours), and complete 
control (no emetic episode, no rescue medication, and no 
more than mild nausea), percentage of patients with no emetic 
episodes, and percentage of patients with no nausea on a daily 
basis, were also included. The results reported hereon are for 
the 0.25 mg dose of palonosetron, since this is the dose that 
has been approved for use.
Palonosetron and acute CINV
Pooled analysis (Rubenstein et al 2003) of the identical 
MEC studies (Eisenberg, Rubenstein et al 2003; Gralla et al 
2003) demonstrated a statistically signiﬁ  cant improvement 
in CR rates for the acute phase with palonosetron 0.25 mg 
(n = 378) compared to results pooled for the ondansetron 
32 mg/dolasetron 100 mg (n = 376) arms (72.0% vs 60.6%, 
p = 0.0012) (Figure 4). Furthermore, the number of patients 
experiencing no emetic episodes in the acute period was 
again statistically superior in the palonosetron group (78.6% 
vs 64.9%, p = 0.0001) (Figure 5) (Grunberg et al 2003; Data 
on ﬁ  le Helsinn Healthcare SA). The improvements in CR and 
emesis-free rates reported in the pooled analysis in favor of 
palonosetron over ondansetron and dolasetron are particu-
larly interesting since this is the ﬁ  rst time that a 5-HT3 RA 
has been clinically differentiated from others in the class.
In patients receiving HEC, a group in whom CINV is 
generally more difﬁ  cult to control, palonosetron 0.25 mg 
(n = 223) proved to be at least as effective as ondansetron 
32 mg (n = 221) in the acute period, with 59.2% and 57% of 
patients, respectively, achieving CR rates (Aapro et al 2006). 
Secondary endpoints further conﬁ  rmed the improved efﬁ  cacy 
of palonosetron in the acute phase, with an increased propor-
tion of patients experiencing no emetic episodes (68.2% vs 
60.2% with ondansetron), and a signiﬁ  cantly longer time to Therapeutics and Clinical Risk Management 2007:3(6) 1014
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ﬁ  rst emetic episode (120 hours vs 42.7 hours with ondan-
setron, p = 0.023) (Aapro et al 2006). As is usual in clinical 
practice, 67% of the patients in this study also received 
prophylactic dexamethasone prior to chemotherapy. In this 
subgroup of patients, the trend towards improved acute 
CR rates in favor of the palonosetron arm (n = 150) over 
the ondansetron group (n = 147) was almost 10% higher, 
a difference which, although not statistically signiﬁ  cant, 
indicates a clinically relevant superiority (64.7% vs 55.8%) 
(Aapro et al 2006).
Palonosetron and delayed CINV
In addition to being more efﬁ  cacious against acute CINV, 
palonosetron is further distinguished from other 5-HT3 RAs 
as it shows improved efﬁ  cacy in preventing delayed CINV 
in patients receiving MEC. In the pooled analysis (Eisenberg 
et al 2004) from the two MEC studies (Eisenberg, Figueroa-
Vadillo et al 2003; Gralla et al 2003), a CR for the delayed 
period was seen in 64.0% of patients given palonosetron 
0.25 mg compared to 46.8% receiving ondansetron 32 mg/
dolasetron 100 mg (p = 0.001) (Figure 4). The improved 
efﬁ  cacy was more pronounced from days 2–3, the point 
at which patients are most at risk of experiencing delayed 
CINV (day 2: 72.0% vs 55.1%, p   0.001; day 3: 76.5% vs 
61.4%, p   0.001) (Data on ﬁ  le Helsinn Healthcare SA). 
Response rates were also better with palonosetron compared 
with ondansetron/dolasetron for the overall phase (57.7% vs 
42.0%, p   0.001) (Figure 4). Moreover, the percentage of 
patients with no emetic episodes was signiﬁ  cantly higher in 
the palonosetron group than in the ondansetron/dolasetron 
group during the delayed and overall time periods (Figure 5) 
(72.0% vs 56.9%, p   0.001, and 65.9% vs 49.5%, p   0.001, 
respectively; Data on ﬁ  le Helsinn Healthcare SA).
In patients receiving HEC, palonosetron 0.25 mg dem-
onstrated a trend towards superior CR rates over ondanse-
tron 32 mg in the delayed and overall categories (45.3% vs 
38.9%, and 40.8% vs 33.0%, respectively), which became 
statistically signiﬁ  cant in the subgroup of patients receiving 
concomitant dexamethasone administered on day 1 (delayed 
phase: 42% vs 28.6%, p = 0.021; overall phase: 40.7% vs 
25.2%, p = 0.005) (Aapro et al 2006).
It is well established that the strongest predictive factor 
for delayed CINV is the presence of acute CINV , and there-
fore it has been speculated that the impact of palonosetron 
on delayed CR may be due to the superior acute efﬁ  cacy or a 
‘carryover effect’. Recent analysis of the two phase III MEC 
studies (Eisenberg, Figueroa-Vadillo et al 2003; Gralla et al 
2003) has attempted to unravel this effect by separating out 
patients with and without acute CRs and evaluating the pro-
portions of these patients who then had delayed CRs (Grun-
berg, Vanden Burgt et al 2004). If improved rates of delayed 
CR are to be attributed to a carryover effect, one would 
expect no difference between the two groups of patients 
who received no relief from acute vomiting; however, this 
Figure 4 Percentage of MEC patients achieving complete response rates in the acute, delayed, and overall phases following treatment with palonosetron 0.25 mg or ondan-
setron 32 mg/dolasetron 100 mg (Drawn from data in Rubenstein et al 2003; Grunberg, Vanden Burgt et al 2004).
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was not the case. In the palonosetron group, 23% of patients 
compared to 12% (p = 0.027) of patients in the comparator 
(ondansetron/dolasetron) group who had acute CINV went 
on to experience a CR for delayed CINV . The implication of 
this study is that palonosetron displays an inherently different 
pharmacology, which alone amongst the 5-HT3 RAs confers 
valuable efﬁ  cacy against delayed CINV.
Palonosetron and nausea
Underestimated by physicians and research nurses, nausea 
remains a significant problem for most chemotherapy 
patients despite the use of modern antiemetics (Table 1) 
(Coates et al 1983; Grifﬁ  n et al 1996; de Boer-Dennert et al 
1997; Lindley et al 1999; Grunberg et al 2000; Grunberg, 
Deusson et al 2004). There are two main reasons for this: 
difficulties in researching this highly subjective issue 
preclinically, and a lack of clinical research due to an 
underestimation of the extent of the problem. It may be 
that nausea is in fact regulated also by as yet unknown 
neurotransmitter pathways separate from those that control 
vomiting, thus accounting for the difﬁ  culties in effective 
treatment with the currently available range of drugs. 
However nausea is regulated physiologically, palonosetron 
appears superior to the first-generation 5-HT3 RAs in 
providing relief.
Severity of nausea was evaluated daily in the palonose-
tron trials over 0–120 hours using a four-point Likert scale 
(Eisenberg, Figueroa-Vadillo et al 2003; Gralla et al 2003). 
Pooled analysis (Decker et al 2006) of both MEC studies 
(Eisenberg, Figueroa-Vadillo et al 2003; Gralla et al 2003) 
demonstrated a statistically significant improvement in 
the proportion of nausea-free patients in the palonosetron 
0.25-mg arm in days from 2 to 5 compared with the ondanse-
tron 32 mg/dolasetron 100 mg group (Figure 6). Of particular 
note is the increased efﬁ  cacy of palonosetron on days 2–3, 
which is known as the most difﬁ  cult period for CINV control 
(day 2: 54.2% vs 39.9%, p   0.0001; day 3: 57.9% vs 45.5%, 
p = 0.0006) (Decker et al 2006).
The functional impact of delayed nausea on daily life 
activities was demonstrated using the validated FLIE 
instrument to be signiﬁ  cantly less with palonosetron (65% 
of patients reported no impact on daily life – NIDL) than 
with ondansetron/dolasetron (54% reported NIDL) in 
the pooled analysis of the MEC trials (p   0.01; Decker 
et al 2006; de Moor and Cunningham 2005). In the study 
of patients receiving HEC that utilized the same FLIE 
measurement, functional impact from delayed nausea was 
also less in the patients given palonosetron with concomi-
tant dexamethasone (55% reported NIDL) than in those 
receiving ondansetron with dexamethasone (46% reported 
NIDL). Although the differences were not statistically 
superior in this subset, they were however clinically rel-
evant and indicative of a meaningful difference to patients 
(Aapro et al 2006).
Figure 5 Percentage of emesis-free MEC patients in the acute, delayed and overall phases following treatment with palonosetron 0.25 mg or ondansetron 32 mg/
dolasetron 100 mg (Drawn from data in Rubenstein et al 2003).
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Palonosetron and steroids
Palonosetron is clearly efﬁ  cacious for delayed CINV when 
given alone. This raises the possibility of being able to 
reduce steroid treatment, which is unpopular with patients 
because of its associated side effects (Vardy et al 2006) 
and consequently reduces adherence and quality of life. 
The HEC trial by Aapro et al (2006) administered a single 
dose of dexamethasone to 67% of the patients on day 1 of 
chemotherapy, thus allowing a subgroup analysis of patients 
receiving palonosetron with concomitant dexamethasone. In 
the delayed period, 42% of patients receiving palonosetron 
0.25 mg plus dexamethasone experienced a CR compared 
to 28.6% in the ondansetron 32 mg plus dexamethasone 
group (p = 0.021).
Synergy between palonosetron and dexamethasone has 
been further evaluated in a recent open-label, phase II study 
by Hajdenberg et al (2006) in patients receiving MEC. 
Fifteen min prior to commencing chemotherapy, an infusion 
of palonosetron 0.25 mg plus dexamethasone 8 mg over a 
10–15-min period was administered to 33 chemotherapy-
naïve and non-naïve patients. In this albeit small sample 
(32 completers), 84.4% of patients had a CR during the 
acute period, and 59.4% demonstrated a CR both in the 
delayed and overall time periods. The proportion of patients 
with no emetic episodes was 90.6%, 81.3%, and 71.9% 
for the acute, delayed, and overall phases, respectively. 
Perhaps more importantly from a patient’s perspective, 
palonosetron used together with dexamethasone given on 
day 1 only was also associated with an increased number 
of nausea-free patients throughout days 1–3 (Hajdenberg 
et al 2006) when compared to palonosetron given alone 
(using pooled data) (Decker et al 2006) from the two MEC 
trials (Table 2) (Eisenberg, Figueroa-Vadillo et al 2003; 
Gralla et al 2003). Some 78.1% of patients were nausea-
free on day 1, increasing to 81.3% on day 2. Overall, rates 
of nausea control ranged between around 66% and 81% 
over days 1–5.
These studies are encouraging in that they suggest a 
single dose of steroid plus palonosetron can provide efﬁ  cacy 
throughout acute and delayed CINV , thus simplifying the 
dosing regimens that currently involve daily administra-
tion of 5-HT3 RAs and dexamethasone (Roila et al 2006). 
This convenient and simple method of CINV control could 
improve patient compliance and, indeed, physician adherence 
to international guidelines.
Palonosetron + neurokinin-1 antagonists
Different mechanisms may lie behind acute and delayed 
CINV (Hesketh 2000; Hesketh 2003), therefore it is to 
be expected that combinations of antiemetic drug classes 
will optimize CINV therapy. Aprepitant (Emend®, Merck 
and Co), a neurokinin-1 (NK-1) antagonist, is a valuable 
addition to antiemesis regimes and it is recommended 
in patients scheduled to receive cisplatin-based and 
Figure 6 Percentage of nausea-free MEC patients on a daily basis following treatment with palonosetron 0.25 mg or ondansetron 32 mg/dolasetron 100 mg (Drawn from 
data in Rubenstein et al 2003).
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anthracycline-cyclophosphamide (AC)-based chemotherapy 
(Roila et al 2006).
A recent open-label, phase II study (n = 58) evaluating 
the efficacy and safety of triple therapy with palonosetron, 
dexamethasone, and aprepitant for prophylaxis of CINV 
in HEC and MEC (including AC-based chemotherapy) 
patients with various types of cancers uncovered syner-
gies between aprepitant and palonosetron (Grote et al 
2006). Administration of palonosetron 0.25 mg in com-
bination with dexamethasone (12 mg on day 1, 8 mg on 
days 2–3) and standard doses of aprepitant (125 mg on 
day 1, 80 mg on days 2–3) achieved 87.9% CR rates in 
the acute period, while 77.6% of patients achieved CR 
in both the delayed and overall phases. Some 93.1% of 
these patients were emesis-free during both the acute and 
delayed phases, and 91.4% were emesis-free in the overall 
phase. Furthermore, 70.7% of patients were nausea-free in 
the acute period, and nausea control was generally main-
tained during all 24-hour intervals observed. Whether this 
highly efficacious treatment regimen can be simplified 
is the subject of further studies. It may prove possible 
to maintain this high level of efficacy while reducing 
the dose of dexamethasone in line with the study by 
Hajdenberg et al (2006).
Tolerability and safety
Adverse reactions
Despite having a longer half-life and duration of action, 
clinical trial data for MEC and HEC patients demonstrate 
a comparable safety proﬁ  le for palonosetron in terms of 
frequency and severity to that of the ﬁ  rst-generation 5-HT3 
RAs (Aloxi® prescribing information 2003/2005; Eisenberg, 
Figueroa-Vadillo et al 2003; Gralla et al 2003; Aapro et al 
2006). Headache (9%) and constipation (5%), generally of 
mild intensity, are the most frequently reported treatment-
related adverse reactions (Aloxi prescribing information 
2003/2005). Postmarketing data from the USA, where 1.3 
million doses have been distributed (Bissoli et al 2005) in 
15 months, have conﬁ  rmed the good tolerability and safety 
proﬁ  le evident during the phase III clinical trials, with no 
suggestion of an unexpected pattern or incidence of adverse 
reactions.
Combination therapy
In the phase II study of MEC patients by Hajdenberg and 
colleagues, a combination regimen of palonosetron 0.25 mg 
plus dexamethasone 8 mg was shown to be safe and well 
tolerated, with the majority of adverse events that were 
reported being of mild–moderate severity (Hajdenberg et al 
2006). Moreover, the safety proﬁ  le of palonosetron 0.25 mg 
used as a triple therapy with dexamethasone and aprepitant in 
MEC and HEC patients was consistent with expectations of 
these treatment regimens, with adverse events again reported 
to be of mild or moderate intensity and resolved quickly 
(Grote et al 2005).
Cardiovascular safety
A theoretical cardiovascular risk has been noted for 
several ﬁ  rst-generation 5-HT3 RAs (Navoban® prescrib-
ing information 2001; Aloxi® prescribing information 
2003/2005; Anzemet® prescribing information 2003), 
notably dolasetron (Hesketh et al 2000) and tropisetron due 
to increased cardiovascular conduction times, particularly 
mean prolongation of the QTc interval. Administration 
of palonosetron 0.25 mg resulted in a 1- to 3-ms increase 
in QTc interval during phase III studies, which compared 
well to ondansetron and dolasetron (both 5-ms) (Eisenberg, 
Figueroa-Vadillo et al 2003; Gralla et al 2003; Aapro et al 
2006). Prolongation of the QTc interval was not clinically 
signiﬁ  cant in any of these study groups, conﬁ  rming that 
although cardiovascular problems are a theoretical risk, the 
risk does not translate into a clinical problem.
The effect of antiemetic therapy on cardiovascular param-
eters in the elderly subpopulation is a very important evalua-
tion since age-related cardiac comorbidities are common in 
these patients (Gridelli et al 2004). It has been shown that the 
incidence of cardiovascular adverse events in elderly patients 
treated with palonosetron 0.25 mg is low ( 2% of patients) 
and similar to that of ondansetron 32 mg/dolasetron 100 mg, 
despite 30% of these patients having some cardiovascular 
Table 2 Percentage of nausea-free patients in a pooled analysis of patients receiving single infusion of palonosetron 0.25 mg prior to 
MEC (Decker et al 2006) compared with patients receiving concomitant infusion of palonosetron 0.25 mg + dexamethasone 8 mg 
(Hajdenberg et al 2006) on Day 1 only.
Study  Day 1  Day 2  Day 3  Day 4  Day 5
Palonosetron (n =  378) 54.5% 54.2% 57.9% 65.3% 77.5%
Palonosetron +    78.1% 81.3% 68.8% 65.6% 78.1%
dexamethasone (n = 32)Therapeutics and Clinical Risk Management 2007:3(6) 1018
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disease or impairment at study enrolment (Aapro et al 2005). 
Very small changes in the QTc interval were observed with 
palonosetron (-1-ms) and with ondansetron/dolasetron 
(4-ms) in this group of patients; however, consistent with 
previous reports (Aloxi prescribing information 2003/2005), 
no severe or serious treatment-related cardiac events were 
observed in patients receiving any of the antiemetic agents 
in these studies.
Conclusion and expert opinion
Clinicians have waited since the introduction of the ﬁ  rst-
generation 5-HT3 RAs for the next step forward in the 
treatment of CINV . Over this time there has been a rise 
in the emetogenic potential of increasingly complex che-
motherapy regimens without a corresponding evolution 
in antiemetic therapeutics. During the past three years, 
signiﬁ  cant progress has been made with the advent of the 
second-generation 5-HT3 RA palonosetron and the NK-1 
RA aprepitant.
Our hopes from the phase III trials of palonosetron have 
indeed been realized. Palonosetron has proven to be an excel-
lent addition to the armamentarium against CINV, speciﬁ  cally 
against delayed and overall CINV, which until now has proved 
difﬁ  cult to treat with conventional 5-HT3 RAs. Not only is 
palonosetron effective against acute and delayed CINV, it 
is effective after a single dose, thus providing a simpler and 
convenient treatment option. An outstanding feature of palo-
nosetron is improved nausea control, which does not seem 
to be adequately controlled with older 5HT3 RAs or with the 
new class of NK1 RAs. Improving the convenience of treat-
ment regimens is important both for physicians and patients. 
Patient adherence, particular from those patients most at risk 
such as the elderly or young women, will improve with easier 
treatment regimens (De Moor et al 2003). A higher degree of 
attention may be paid to patients’ symptoms having an impact 
on their functioning during daily life by evaluating patient’s 
quality of life with speciﬁ  c tools (FLIE, Osoba).
Treatment efficacy, convenience, compliance, and 
cost-effectiveness can also be improved in clinical practice 
using combination therapy strategies. Studies to date have 
clearly demonstrated that palonosetron coadministered with 
dexamethasone offers enhanced anti-CINV protection with a 
single-dose infusion (Hajdenberg et al 2006), and substantial 
beneﬁ  ts in preventing CINV are also evident when used in 
a triple-therapy combination alongside dexamethasone and 
aprepitant (Grote et al 2006).
Further optimization of antiemetic therapy will require 
evaluation of drug combinations in a variety of patient 
groups in order to elucidate any additional synergistic efﬁ  -
cacy. Other groups and areas that require speciﬁ  c attention 
include patients receiving multiday emetogenic therapy, an 
area where also guidelines for antiemetic prevention may 
need further improvement, those undergoing radiotherapy 
with or without concomitant chemotherapy, and those 
receiving high-dose chemotherapy with hematopoietic 
stem-cell support.
In addition an effort directed to improve both patients’ and 
medical professionals’ compliance with an optimal antiemetic 
schedule will beneﬁ  t of a better knowledge of longer acting 
agents that can be given once or antiemetic schedules given on 
Day 1 only, that are able to ensure protection against nausea 
and vomiting both in the acute and the delayed setting.
Five-year review
The full potential of the second-generation 5-HT3 RA palono-
setron has yet to be explored; combinations with other drug 
classes will provide a more tailored, individual approach to 
CINV prophylaxis, and drug regimens will be optimized 
according to patient risk factors. It is not unreasonable to 
speculate that this approach will lead to a majority of patients 
being CINV-free within this timeframe.
Although therapy optimization will require combina-
tions of various drugs, the treatment regimens will become 
simpler since more will be known regarding the duration of 
action of drugs. A standard regimen will probably involve 
a single steroid dose plus a long-acting 5-HT3 RA prior to 
chemotherapy of moderate to high emetic risk, with admin-
istration of an NK-1 antagonist throughout each higher risk 
chemotherapy cycle.
We will have a number of neurokinin RAs, perhaps with 
differing pharmacology, thus providing improved efﬁ  cacy 
compared to aprepitant, much like the improvement over 
ﬁ  rst-generation 5-HT3 RAs that the pharmacologically 
distinct palonosetron has provided. Studies of these new 
drugs and various combinations will also have lead to a 
better understanding of the complexities of the vomiting 
and nausea response.
We are now entering an era of change in the conduc-
tion of clinical studies. The fact that we can provide many 
patients with prophylaxis from vomiting is a tribute to 
the progress made over the past two decades, but we are 
now realizing that this is not enough. Nausea remains a 
challenge that is underaddressed and one that physicians 
are starting to regard more seriously. As a result, future 
clinical trials should evaluate endpoints that are most 
relevant to patients.Therapeutics and Clinical Risk Management 2007:3(6) 1019
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Key issues
Key issues are as follows:
•  CINV remains a clinical challenge, particularly the treat-
ment of delayed CINV .
•  The second-generation 5-HT3 RA palonosetron is phar-
macologically differentiated from the ﬁ  rst-generation 
5-HT3 RAs with a 4–10-fold longer half-life and a  30-
fold greater afﬁ  nity for the 5-HT3 receptor.
•  A single dose of palonosetron prior to chemotherapy provides 
protection over the entire overall phase (days 1–5) and par-
ticularly over the ﬁ  rst three-day period when CINV risk is 
greatest, hence providing a simple, yet effective, regimen.
•  In comparison to the ﬁ  rst-generation 5-HT3 RAs, the sec-
ond-generation 5-HT3 RA palonosetron provides improved 
protection against both acute and delayed CINV.
•  Palonosetron demonstrates improved efﬁ  cacy against 
nausea and maintenance of daily activities, in addition 
to reducing the number of emetic episodes.
•  Combining administration of palonosetron with aprepi-
tant and dexamethasone appears to confer a synergistic 
beneﬁ  t in preventing acute and delayed CINV .
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